Ixazomib

    Ixazomib (MLN9708) is an investigational oral proteasome inhibitor, which is being studied in multiple myeloma (MM), systemic light-chain (AL) amyloidosis and other malignancies. Ixazomib was granted orphan drug designation in MM in both the U.S. and Europe in 2011, and for AL amyloidosis in both the U.S. and Europe in 2012. Ixazomib received Breakthrough Therapy status by the U.S. Food and Drug Administration (FDA) for relapsed and/or refractory AL amyloidosis in 2014. It is also the first oral proteasome inhibitor to enter Phase 3 clinical trials. Five global Phase 3 trials are ongoing:

    TOURMALINE-MM1, investigating ixazomib vs. placebo in combination with lenalidomide and dexamethasone in relapsed and/or refractory MM;
    TOURMALINE-AL1, investigating ixazomib plus dexamethasone in patients with relapsed or refractory AL amyloidosis;
    TOURMALINE-MM2, investigating ixazomib vs. placebo in combination with lenalidomide and dexamethasone in patients with newly diagnosed MM;
    TOURMALINE-MM3, investigating ixazomib vs. placebo as maintenance therapy in patients with newly diagnosed MM following induction therapy and autologous stem cell transplant (ASCT);
    TOURMALINE-MM4, investigating ixazomib vs. placebo as maintanence therapy in patients with newly diagnosed MM who have not undergone ASCT.

    [td_text_with_title custom_title=”Latest post”]

    Takeda Submits New Drug Application for Ixazomib

    Cambridge, Mass., July 14, 2015 and Osaka, Japan, July 15, 2015 –Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that a New Drug Application (NDA) has been submitted to the United States (U.S.) Food and Drug Administration (FDA) for ixazomib, an investigational oral proteasome inhibitor for the treatment of patients with relapsed and/or refractory multiple myeloma. The NDA submission […]

    0 comments
    [/td_text_with_title][td_text_with_title custom_title=”From Wikipedia”]
    Ixazomib
    Ixazomib.svg
    Clinical data
    Trade names Ninlaro
    Synonyms MLN2238
    AHFS/Drugs.com ninlaro
    License data
    Routes of
    administration
    Oral (capsules)
    ATC code
    Legal status
    Legal status
    • US: ℞-only
    • In general: ℞ (Prescription only)
    Pharmacokinetic data
    Bioavailability 58%[1]
    Protein binding 99%
    Metabolism Hepatic (CYP: 3A4 (42%), 1A2 (26%), 2B6 (16%) and others)
    Elimination half-life 9.5 days
    Excretion Urine (62%), faeces (22%)
    Identifiers
    CAS Number
    PubChem CID
    DrugBank
    ChemSpider
    UNII
    KEGG
    ChEBI
    Chemical and physical data
    Formula C14H19BCl2N2O4
    Molar mass 361.03 g·mol−1
    3D model (JSmol)

    Ixazomib (trade name Ninlaro) is a drug for the treatment of multiple myeloma, a type of white blood cell cancer,[2] in combination with other drugs. It is taken by mouth in form of capsules.

    Common side effects include diarrhoea, constipation and low platelet count. Like the older bortezomib (which can only be given by injection), it acts as a proteasome inhibitor, has orphan drug status in the US and Europe, and is a boronic acid derivative.

    The drug was developed by Takeda. In the US, it is approved since November 2015, and in the EU since November 2016.

    Medical uses

    Ixazomib is used in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in adults after at least one prior therapy. There are no experiences with children and youths under 18 years of age.[3][4]

    The study relevant for approval included 722 people. In this study, ixazomib increased the median time of progression-free survival from 14.7 months (in the placebo+lenalidomide+dexamethasone study arm including 362 people) to 20.6 months (under ixazomib+lenalidomide+dexamethasone, 360 people), which was a statistically significant effect (p = 0.012). 11.7% of patients in the ixazomib group had a complete response to the treatment, versus 6.6% in the placebo group. Overall response rate (complete plus partial) was 78.3% versus 71.5%.[4][5]

    A phase 3 study demonstrated a significant improvement in progression-free survival (PFS) with ixazomib-lenalidomide-dexamethasone (IRd) compared with placebo. High-risk cytogenetic abnormalities were defined as del(17p), t(4;14), and/or t(14;16); additionally, patients were assessed for 1q21 amplification. Of 722 randomized patients, 552 had cytogenetic results; 137 (25%) had high-risk cytogenetic abnormalities and 172 (32%) had 1q21 amplification alone. PFS was improved with IRd versus placebo in both high-risk and standard-risk cytogenetics subgroups: in high-risk patients, with median PFS of 21.4 versus 9.7 months; in standard-risk patients, with median PFS of 20.6 versus 15.6 months. This PFS benefit was consistent across subgroups with individual high-risk cytogenetic abnormalities, including patients with del(17p). PFS was also longer with IRd versus placebo- in patients with 1q21 amplification, and in the "expanded high-risk" group, defined as those with high-risk cytogenetic abnormalities and/or 1q21 amplification. IRd demonstrated substantial benefit compared with placebo in relapsed/refractory multiple myeloma patients with high-risk and standard-risk cytogenetics, and improves the poor PFS associated with high-risk cytogenetic abnormalities.[6]

    Pregnancy and breastfeeding

    Ixazomib and lenalidomide are teratogenic in animal studies. The latter is contraindicated in pregnant women, making this therapy regimen unsuitable for this group. It is not known whether ixazomib or its metabolites pass into the breast milk.[4][7]

    Side effects

    Common side effects of the ixazomib+lenalidomide+dexamethasone study therapy included diarrhoea (42% versus 36% under placebo+lenalidomide+dexamethasone), constipation (34% versus 25%), thrombocytopenia (low platelet count; 28% versus 14%), peripheral neuropathy (28% versus 21%), nausea (26% versus 21%), peripheral oedema (swelling; 25% versus 18%), vomiting (22% versus 11%), and back pain (21% versus 16%). Serious diarrhoea or thrombocytopenia occurred in 2% of patients, respectively.[4][7]

    Side effects of ixazomib alone were only assessed in a small number of people. Diarrhoea grade 2 or higher was found in 24% of these patients, thrombocytopenia grade 3 or higher in 28%, and fatigue grade 2 or higher in 26%.[8]

    Interactions

    The drug has a low potential for interactions via cytochrome P450 (CYP) liver enzymes and transporter proteins. The only relevant finding in studies was a reduction of ixazomib blood levels when combined with the strong CYP3A4 inducer rifampicin. The Cmax was reduced by 54% and the area under the curve by 74% in this study.[4][7]

    Pharmacology

    Mechanism of action

    At therapeutic concentrations, ixazomib selectively and reversibly inhibits the protein proteasome subunit beta type-5 (PSMB5)[7] with a dissociation half-life of 18 minutes. This mechanism is the same as of bortezomib, which has a much longer dissociation half-life of 110 minutes; the related drug carfilzomib, by contrast, blocks PSMB5 irreversibly. Proteasome subunits beta type-1 and type-2 are only inhibited at high concentrations reached in cell culture models.[9]

    PSMB5 is part of the 20S proteasome complex and has enzymatic activity similar to chymotrypsin. It induces apoptosis, a type of programmed cell death, in various cancer cell lines. A synergistic effect of ixazomib and lenalidomide has been found in a large number of myeloma cell lines.[7][10]

    Pharmacokinetics

    Ixazomib citrate—a prodrug for ixazomib
    Ixazomib citrate (MLN9708), the prodrug for ixazomib

    The medication is taken orally as a prodrug, ixazomib citrate, which is a boronic ester; this ester rapidly hydrolyzes under physiological conditions to its biologically active form, ixazomib, a boronic acid.[1] Absolute bioavailability is 58%, and highest blood plasma concentrations of ixazomib are reached after one hour. Plasma protein binding is 99%.[4][7]

    The substance is metabolized by many CYP enzymes (percentages in vitro, at higher than clinical concentrations: CYP3A4 42.3%, CYP1A2 26.1%, CYP2B6 16.0%, CYP2C8 6.0%, CYP2D6 4.8%, CYP2C9 4.8%, CYP2C9 <1%) as well as non-CYP enzymes,[4] which could explain the low interaction potential. Clearance is about 1.86 litres per hour with a wide variability of 44% between individuals, and plasma half-life is 9.5 days. 62% of ixazomib and its metabolites are excreted via the urine (of which less than 3.5% in unchanged form) and 22% via the faeces.[4][7]

    Chemistry

    Ixazomib is a boronic acid and peptide analogue[10] like the older bortezomib. It contains a derivative of the amino acid leucine with the carboxylic acid group being replaced by a boronic acid; and the remainder of the molecule has been likened to phenylalanine.[9] The structure has been found through a large-scale screening of boron-containing molecules.[9]

    History

    The drug was developed by Takeda. It got US and European orphan drug status for multiple myeloma in 2011, and for AL amyloidosis in 2012. Takeda submitted a US new drug application for multiple myeloma in July 2015.[11] In September 2015, the U.S. Food and Drug Administration (FDA) granted ixazomib combined with lenalidomide and dexamethasone a priority review designation for multiple myeloma.[12] On 20 November 2015, the FDA approved this combination for second-line treatment.[3]

    The request for marketing authorisation in Europe was initially refused by the European Medicines Agency (EMA) in May 2016 due to insufficient data showing a benefit of treatment.[13] After Takeda requested a re-examination, the EMA granted a marketing authorisation on 21 November 2016 on the condition that further efficacy studies be conducted. The approval indication is the same as in the US.[4]

    Research

    As of January 2017[update], ixazomib is also in Phase III clinical trials for the treatment of AL amyloidosis[14] and plasmacytoma of the bones,[15] and in Phase I/II trials for various other conditions.[16][17]

    References

    1. ^ a b "Ninlaro (ixazomib) Capsules, for Oral Use. Full Prescribing Information" (PDF). Ninlaro (ixazomib) For Healthcare Professionals. Takeda Pharmaceutical Company Limited. Retrieved 21 November 2015. 
    2. ^ Raab, M. S.; Podar, K; Breitkreutz, I; Richardson, P. G.; Anderson, K. C. (2009). "Multiple myeloma". Lancet. 374 (9686): 324–39. doi:10.1016/S0140-6736(09)60221-X. PMID 19541364. 
    3. ^ a b "Press Announcements — FDA approves Ninlaro, new oral medication to treat multiple myeloma". U.S. Food and Drug Administration. 20 November 2015. 
    4. ^ a b c d e f g h i "Ninlaro: EPAR – Product Information" (PDF). European Medicines Agency. 21 November 2016. 
    5. ^ Moreau, P (2016). "Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma". New England Journal of Medicine. 374 (17): 1621–1634. doi:10.1056/NEJMoa1516282. PMID 27119237. 
    6. ^ Avet-Loiseau, H., Bahlis, N. J., Chng, W., Masszi, T., Viterbo, L., Pour, L., Ganly, P., Palumbo, A., Cavo, M., Langer, C., Pluta, A., Nagler, A., Kumar, S., Ben-Yehuda, D., Rajkumar, S. V., San-Miguel, J., Berg, D., Lin, J., van de Velde, H., Esseltine, D., di Bacco, A., Moreau, P., & Richardson, P. G. (2017). Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. Blood, (), blood-2017-06-791228. Accessed October 24, 2017. https://doi.org/10.1182/blood-2017-06-791228.
    7. ^ a b c d e f g Haberfeld, H, ed. (2016). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. 
    8. ^ Gupta, N; Labotka, R; Liu, G; Hui, A. M.; Venkatakrishnan, K (2016). "Exposure–safety–efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study". Investigational New Drugs. 34 (3): 338–346. doi:10.1007/s10637-016-0346-7. PMC 4859859Freely accessible. PMID 27039387. 
    9. ^ a b c Muz, B; Ghazarian, R. N.; Ou, M; Luderer, M. J.; Kusdono, H. D.; Azab, A. K. (2016). "Spotlight on ixazomib: potential in the treatment of multiple myeloma". Drug design, development and therapy. 10: 217–26. doi:10.2147/DDDT.S93602. PMC 4714737Freely accessible. PMID 26811670. 
    10. ^ a b KEGG: Ixazomib
    11. ^ "Takeda Submits New Drug Application for Ixazomib for Patients with Relapsed/Refractory Multiple Myeloma". Takeda. 14 July 2015. 
    12. ^ "Ixazomib Granted Priority Review by the FDA for Multiple Myeloma". Targeted Oncology. 9 September 2015. 
    13. ^ "Questions and answers on refusal of the marketing authorisation for Ninlaro" (PDF). European Medicines Agency. 27 May 2016. 
    14. ^ Clinical trial number NCT01659658 for "Study of Dexamethasone Plus Ixazomib (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis" at ClinicalTrials.gov
    15. ^ Clinical trial number NCT02516423 for "Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone" at ClinicalTrials.gov
    16. ^ Clinical trial number NCT02420847 for "A Two-Dimensional Dose-Finding Study of Ixazomib in Combination With Gemcitabine and Doxorubicin, Followed by a Phase II Extension to Assess the Efficacy of This Combination in Metastatic, Surgically Unresectable Urothelial Cancer" at ClinicalTrials.gov
    17. ^ Clinical trial number NCT02250300 for "MLN9708 for the Prophylaxis of Chronic Graft-versus-host Disease in Patient Undergoing Allogeneic Transplantation" at ClinicalTrials.gov
    source: https://en.wikipedia.org/wiki/Ixazomib[/td_text_with_title]